Skip to main content

Reykjavík Energy Green Finance Impact Report 2024

Reykjavík Energy (Orkuveita Reykjavíkur) has published the attached Reykjavík Energy Green Finance Impact Report 2024 – Audited, certified by the company’s independent auditors. The report is in English. The report is issued under the provisions of Reykjavík Energy’s Green Finance Framework, which was published on October 30, 2024, and received a “Dark Green” rating from the rating agency S&P Global. It details the allocation of green loan proceeds in 2024, totalling ISK 31.3 billion. “Since Reykjavík Energy took the lead in green financing in Iceland in 2019, the company has benefited from more favourable financing terms. Today, it is the most significant issuer of green bonds in Iceland. The reputation we have built will serve us well in the ambitious green projects ahead in energy production, utility operations,...

Continue reading

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis (“FAP”). The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in...

Continue reading

Serstech receives an order of 2.1 MSEK from its partner Kaiser

Serstech has today received an order from its partner Kaiser in Singapore. The order consists of SERS consumables. The value of the order is 2.1 MSEK, and it will be delivered and invoiced in Q2 2025. For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606 067 Email: ss@serstech.com or Thomas Pileby, Chairman of the Board, Serstech AB Phone: +46 702 072 643 Email: tp@serstech.com or visit: www.serstech.com This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 13:30 CET on March 10, 2025. Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG). About Serstech Serstech delivers solutions for chemical identification and...

Continue reading

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid...

Continue reading

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office (“KIPO”). The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide (“PEA”) for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel....

Continue reading

Bird Joint Venture Signs Project Alliance Agreement for East Harbour Transit Hub

MISSISSAUGA, Ontario, March 10, 2025 (GLOBE NEWSWIRE) — Bird Construction Inc. (TSX: BDT) is pleased to announce that Rail Connect Partners, its 50/50 joint venture with AtkinsRéalis, has finalized and signed a Project Alliance Agreement with Metrolinx to deliver the East Harbour Transit Hub, that will strengthen transit options for the City of Toronto. The execution phase of the project includes completion of the rail corridor and bridge widening over an important thoroughfare, which will continue to be undertaken in planned phases to keep GO Transit services running with minimal impact. The execution phase will also include the commencement of the station works and associated infrastructure and future road extension to facilitate a future streetcar connection. “The Metrolinx team is proud to work with partners in government...

Continue reading

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company’s new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a variety...

Continue reading

Whitestone REIT Commences Transformation of Merchandising Mix at Davenport Village in Austin, Texas

Positioning asset to become an 18-hour activity hub that better serves the lifestyle needs of the surrounding community Meets neighborhood demand for an upscale coffeehouse, premium fitness concepts and executive suites by bringing in Starbucks Reserve, Pvolve, RVE Fitness and CUBExec HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced that it has commenced a strategic transformation of the merchandising mix at Davenport Village (“Davenport”) in Austin, Texas that is expected to re-energize the center and strengthen its competitive position within the upscale neighborhoods it serves: Davenport Ranch, Westlake, Rob Roy and Barton Creek. Whitestone is creating a vibrant, 18-hour activity hub that more appropriately...

Continue reading

Anfield Announces Special Shareholder Meeting and Mailing of Related Documents in Pursuit of NASDAQ Listing

VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) announces that it has filed notice of a meeting of shareholders, a management information circular, and related documents (collectively, the “Meeting Materials”) to convene a special meeting (the “Meeting”) of shareholders. The Meeting will take place on March 31, 2025 at 10:00 AM (Vancouver Time). Copies of the Meeting Materials are available for review under the profile for the Company on SEDAR+ (www.sedarplus.ca) and on Anfield’s corporate website (https://anfieldenergy.com). The Meeting has been convened to seek shareholder approval for a consolidation (the “Consolidation”) of the Company’s common shares (“Shares”) on the basis of one new Share for up to 200 currently issued...

Continue reading

Traxys and HNK Alpha Execute First Lithium Carbonate Futures Block Trade on Abaxx Commodity Futures Exchange and Clearinghouse

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced the execution of the first lithium carbonate futures block trade, traded between Traxys and HNK Alpha on March 7, 2025. Traxys and HNK Alpha traded 20 lots of the May 2025 Abaxx Lithium Carbonate Singapore futures contract at USD$10,300/tonne. “We are delighted to be an active participant in the newly created Abaxx physical lithium carbonate contract,” said Martim Facada, Head of Lithium, Traxys. “As a long-term participant in the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.